ACTONEL

LOE Approaching

risedronate sodium

NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7

Mechanism of Action

agent. At the cellular level, ACTONEL inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that ACTONEL treatment reduces bone turnover…

Clinical Trials (5)

NCT00919711Phase 3Completed

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

Started Sep 2009
870 enrolled
Osteoporosis
NCT00460733Phase 4Completed

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Started Mar 2007
141 enrolled
Colles' Fracture
NCT00544180Phase 4Terminated

ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Started May 2005
7 enrolled
Osteoporosis
NCT01038011Phase 2Completed

Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study

Started Jun 2004
Ankylosing Spondylitis
NCT00632216Phase 4Completed

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Started May 2004
464 enrolled
Osteoporosis, Postmenopausal